The transaction is a Europe-wide deal, as Amethyst has expanded from Romania to other countries such as Poland, France, Italy and UK.
“Amethyst fits perfectly into our strategy of supporting market-leading providers of essential services,” said Edward Chandler, founding partner at Fremman Capital, which will use its deep healthcare experience and international reach, to accelerate Amethyst’s growth and build a European champion in radiotherapy.
Amethyst is a brand created by entrepreneur Ludovic Robert, one of the founders of the A&D Pharma group in Romania. It is now a leading European cancer care provider, specializing in radiotherapy, chemotherapy, and diagnostic imaging.
The year 2024 brought a 27% increase in revenue for Amethyst Romania, to EUR52 million in its home market alone, from its four clinics in the country. In 2025, two more clinics, in Satu Mare and Piatra Neamt, will be added to Amethyst Romania, each requiring a EUR10 million investment.
In Europe, Amethyst is present with 13 centers in France, Italy, Austria, UK and Poland, but is also targeting other countries for expansion.
(English version by Loredana Fratila-Cristescu)